MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma

Supplementary Material

Supplementary Table S1. Prognostic implication of the miR-21 expression analyzed by multivariate Cox-regression model in DLBCL patients with GCB and ABC subtype.

| | | GCB-like | | | ABC-like | | |
|---------------------------|---------------------------------|----------|--------------|-------|----------|--------------|--------|
| | | HR | 95% CI | p | HR | 95% CI | p |
| Overall survival | | | | | | | |
| miR-21 | high vs. low | 5.957 | 2.105-16-859 | 0.001 | 1.215 | 0.522-2.830 | 0.651 |
| R-IPI | poor vs. very good + good | 4.027 | 1.355-11.970 | 0.012 | 4.578 | 2.167-9.669 | <0.001 |
| Progression free survival | | | | | | | |
| miR-21 | high vs. low | 5.376 | 1.592-18.161 | 0.007 | 1.221 | 0.445-3.348 | 0.698 |
| R-IPI | poor vs. very good + good | 2.078 | 0.530-8.152 | 0.294 | 4.457 | 1.886-10.553 | 0.001 |

GCB-like and ABC-like subtype were classified using Choi classifier.


| Name | | Sequence |
|-------------------|---------|--------------------------------|
| miR-21 | forward | 5'-TGTCGGGTAGCTTATCAGACT-3' |
| | reverse | 5'-TGTCAGACAGCCCATCGACT-3' |
| miR-17-92 cluster | forward | 5'-GTCAGAATAATGTCAAAGTGCTT-3' |
| | reverse | 5'-TCACCATAATGCTACAAGTGCCT-3' |
| miR-155 | forward | 5'-CTGTTAATGCTAATCGTGATAGG-3' |
| | reverse | 5'-CTGTTAATGCTAATATGTAGGAG-3' |
| miR-21ª | forward | 5'-TAGCTTATCAGACTGATGTTGA-3'. |
| FOXO1 | forward | 5'-GCCATGTAAGTCCCATCAGGA-3' |
| | reverse | 5'-ATCGGAACAAGAACGTGGAATC-3' |
| PTEN | forward | 5'-CCAGGACCAGAGGAAACCT-3' |
| | reverse | 5'-GCTAGCCTCTGGATTTGA-3' |
| p21 | forward | 5'-AGGAGGCCCGTGAGCGATGGAAC-3' |
| | reverse | 5'-ACAAGTGGGGAGGAGGAAGTAGC-3' |
| p27 | forward | 5'-GGTTAGCGGAGCAATGCG-3' |
| | reverse | 5'-TCCACAGAACCGGCATTTG-3' |
| FasL | forward | 5'-GCCCTTCAATTACCCATATCCC-3' |
| | reverse | 5'-GGCAACCAGAACCATGAAAAACA-3' |
| Bim | forward | 5'-TGGCAAAGCAACCTTCTGATG-3' |
| | reverse | 5'-GCAGGCTGCAATTGTCTACCT-3' |
| ABCB1/MDR1 | forward | 5'-GCCTGGCAGCTGGAAGACAAATAC-3' |
| | reverse | 5'-GCAGGCTGCAATTGTCTACCT-3' |
| ABCG2 | forward | 5'-CCGCGACAGTTTCCAATGACCT-3' |
| | reverse | 5'-GCCGAAGAGCTGCTGAGAACTGTA-3' |

Supplementary Table S2. List and sequences of primers used for qRT-PCR .


^afor DLBCL cell line

| Mimics/inhibitors | | Sequence |
|--------------------|-----------|-------------------------------|
| miR-21 mimics | sense | 5'-UAGCUUAUCAGACUGAUGUUGA-3' |
| | antisense | 5'-UCAACAUCAGUCUGAUAAGCUA-3' |
| Negative mimics | sense | 5'-UUGUACUACACAAAAGUACUGUU-3' |
| | antisense | 5'-CAGUACUUUUGUGUAGUACAAUU-3' |
| miR-21 inhibitor | | UCAACAUCA GUCUGAUAAGCUA |
| Negative inhibitor | | CAGUACUUUUGUGUAGUACAA |


Supplementary Table S3. Sequences of miRNA mimics and inhibitors.



Supplementary Figure S1. Kaplan-Meier survival curves with the log-rank test according to the miR-21 levels in GCB DLBCL patients by Choi classifier.




Supplementary Figure S2 A, Representative FOXO1 immunohistochemistry (IHC) images of DLBCL tumors with low *vs.* high expression levels of miR-21. B, The FOXO1 IHC-based expression scores were calculated as the nuclear intensity minus the cytoplasmic intensity of FOXO1 staining considering that FOXO1 functions in the nucleus. Accordingly, the DLBCL cases were divided into two groups as follows: nuclear (*i.e.*, high FOXO1 IHC score) and cytoplasmic (*i.e.*, low FOXO1 IHC score) predominant staining groups. The relationship between the FOXO1-IHC score and the levels of miR-21 expression was analyzed using the Fisher's exact test.




Actinomycin D: transcription inhibitor

Supplementary Figure S3. SU-DHL4 and SU-DHL5 cells were transfected with either a miR-21 inhibitor or a negative inhibitor followed by treatment with the transcription inhibitor, actinomycin D. At 24 hours after transfection, the level of Bim expression was evaluated using qRT-PCR. The values presented in the histogram are the mean values \pm SD. Statistically significant differences are indicated by **, which signify *P* < 0.005 as determined using the paired t-test.




Supplementary Figure S4. Bim expression between miR-21 low and high groups of patients with DLBCL. A, Mean value of Bim mRNA expression was measured by qRT-PCR in 32 patients. B, protein expression was evaluated by IHC in 101 patients. The relationship between the Bim-IHC expression and the levels of miR-21 expression was analyzed using the Fisher's exact test.



Supplementary Figure S5. After SU-DHL4 and SU-DHL5 were transfected with a miR-21 inhibitor or negative inhibitor, their cell viability and proliferation rates were determined using the CCK8 assay at 24 and 48 hours.

miR-21 binding motifs (5'-AGCUUAU-3')

FOXO1 binding motifs (5'-GTAAACAA-3')



Supplementary Figure S6. A, FOXO1 3' UTR-reporter gene assay construct. B,

Bim promoter-reporter gene assay construct.